Sec Form 3 Filing - Mackay Sean @ IsoPlexis Corp - 2021-10-07

Insider filing report for Changes in Beneficial Ownership
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
FORM 3
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: November 30, 2011
Estimated average burden hours per response... 0.5
1. Name and Address of Reporting Person
Mackay Sean
2. Issuer Name and Ticker or Trading Symbol
IsoPlexis Corp [ ISO]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X __ Director _____ 10% Owner
X __ Officer (give title below) _____ Other (specify below)
Chief Executive Officer
(Last) (First) (Middle)
C/O ISOPLEXIS CORPORATION, 35 NE INDUSTRIAL RD
3. Date of Earliest Transaction (MM/DD/YY)
10/07/2021
(Street)
BRANFORD, CT06405
4. If Amendment, Date Original Filed (MM/DD/YY)
6. Individual or Joint/Group Filing (Check Applicable Line)
__ X __ Form filed by One Reporting Person
_____ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 799,200 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(MM/DD/YY)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $ 0.2788 ( 1 ) 10/31/2025 Common Stock 40,000 ( 1 ) D
Stock Option (right to buy) $ 0.2788 ( 2 ) 10/31/2025 Common Stock 80,000 ( 2 ) D
Stock Option (right to buy) $ 0.44 ( 3 ) 10/19/2026 Common Stock 52,000 ( 3 ) D
Stock Option (right to buy) $ 0.7263 ( 4 ) 10/04/2027 Common Stock 14,000 ( 4 ) D
Stock Option (right to buy) $ 0.7263 ( 5 ) 10/04/2027 Common Stock 14,000 ( 5 ) D
Stock Option (right to buy) $ 0.7263 ( 6 ) 10/04/2027 Common Stock 112,000 ( 6 ) D
Stock Option (right to buy) $ 0.7263 ( 7 ) 01/15/2028 Common Stock 24,000 ( 7 ) D
Stock Option (right to buy) $ 0.7263 ( 8 ) 02/11/2028 Common Stock 48,000 ( 8 ) D
Stock Option (right to buy) $ 0.7263 ( 9 ) 06/28/2028 Common Stock 52,000 ( 9 ) D
Stock Option (right to buy) $ 0.7263 ( 10 ) 09/26/2028 Common Stock 40,000 ( 10 ) D
Stock Option (right to buy) $ 0.9625 ( 11 ) 12/13/2028 Common Stock 96,000 ( 11 ) D
Stock Option (right to buy) $ 1.0275 ( 12 ) 04/14/2030 Common Stock 680,000 ( 12 ) D
Stock Option (right to buy) $ 4.81 ( 13 ) 06/07/2031 Common Stock 744,000 ( 13 ) D
Reporting Owners
Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Mackay Sean
C/O ISOPLEXIS CORPORATION
35 NE INDUSTRIAL RD
BRANFORD, CT06405
X Chief Executive Officer
Signatures
/s/ Shane Sevier, attorney-in-fact for Sean Mackay 10/07/2021
Signature of Reporting Person Date
Explanation of Responses:
( 1 )Represents 40,000 time-vesting options. Time-vesting options are subject to a four-year time-based vesting schedule, with 25% vested on August 31, 2019 and the remainder vesting in 36 equal installments every month thereafter.
( 2 )Represents 80,000 time-vesting options. Time-vesting options were subject to a four-year time-based vesting schedule, with 25% vested on May 25, 2017 and the remainder vested in 36 equal installments every month thereafter.
( 3 )Represents 52,000 time-vesting options. Time-vesting options were subject to a four-year time-based vesting schedule, with 25% vested on October 20, 2017 and the remainder vested in 36 equal installments every month thereafter.
( 4 )Represents 14,000 performance-vesting options. Performance-vesting options are subject to vesting based upon the achievement of a 2018 revenue target, which was achieved, and a four-year time-based vesting schedule, with 25% vested on December 26, 2019 and the remainder vesting in 36 equal installments every month thereafter.
( 5 )Represents 14,000 performance-vesting options. Performance-vesting options are subject to vesting based upon the achievement of specified sales goals that remain outstanding and a four-year time-based vesting schedule, with 25% vesting on the first anniversary of the date the specified sales goals are achieved and the remainder vesting in 36 equal installments every month thereafter.
( 6 )Represents 112,000 time-vesting options. Time-vesting options are subject to a four-year time-based vesting schedule, with 25% vested on October 5, 2018 and the remainder vesting in 36 equal installments every month thereafter.
( 7 )Represents 24,000 time-vesting options. Time-vesting options are subject to a four-year time-based vesting schedule, with 25% vested on January 16, 2019 and the remainder vesting in 36 equal installments every month thereafter.
( 8 )Represents 48,000 time-vesting options. Time-vesting options were subject to a four-year time-based vesting schedule, with 25% vested on August 1, 2018 and the remainder vested in 36 equal installments every month thereafter.
( 9 )Represents 52,000 time-vesting options. Time-vesting options are subject to a four-year time-based vesting schedule, with 25% vested on June 29, 2019 and the remainder vesting in 36 equal installments every month thereafter.
( 10 )Represents 40,000 time-vesting options. Time-vesting options are subject to a four-year time-based vesting schedule, with 25% vested on September 27, 2019 and the remainder vesting in 36 equal installments every month thereafter.
( 11 )Represents 96,000 time-vesting options. Time-vesting options are subject to a four-year time-based vesting schedule, with 25% vested on December 5, 2019 and the remainder vesting in 36 equal installments every month thereafter.
( 12 )Represents 680,000 performance-vesting options. Performance-vesting options were subject to vesting based upon the achievement of certain 2020 revenue targets. On December 15, 2020, the board of directors of IsoPlexis Corporation fully accelerated the performance-vesting options such that such options became exercisable as of such date.
( 13 )Represents 744,000 time-vesting options. Time-vesting options are subject to a four-year time-based vesting schedule, with 25% vesting on June 8, 2022 and the remainder vesting in 36 equal installments every month thereafter.

Remarks:
Exhibit 24 - Power of Attorney

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.